Search
Feed aggregator
Biotheus, Hansoh Expand Partnership in $694M ADC Deal
Biotheus, Hansoh Expand Partnership in $694M ADC Deal 3/15/2024
Astellas Backs Out of Potential $340M Licensing Deal with Cartesian
Astellas Backs Out of Potential $340M Licensing Deal with Cartesian 3/15/2024
Bayer, AI-Focused Aignostics Partner to Find New Oncology Targets
Bayer, AI-Focused Aignostics Partner to Find New Oncology Targets 3/15/2024
Asgard Gets $32M Series A Backing from J&J, Novo and Boehringer
Asgard Gets $32M Series A Backing from J&J, Novo and Boehringer 3/15/2024
BMS’s Breyanzi Becomes First CAR-T Therapy for Two Types of Leukemia
BMS’s Breyanzi Becomes First CAR-T Therapy for Two Types of Leukemia 3/15/2024
FDA Adcomm to Tackle Complexity of CAR-T for Multiple Myeloma
FDA Adcomm to Tackle Complexity of CAR-T for Multiple Myeloma 3/15/2024
NASH or MASH: No Matter What You Call It, Madrigal’s FDA Approval Is a Big Deal
NASH or MASH: No Matter What You Call It, Madrigal’s FDA Approval Is a Big Deal 3/15/2024
BeiGene’s Tevimbra Wins First US Approval Following Tough Regulatory Path
BeiGene’s Tevimbra Wins First US Approval Following Tough Regulatory Path 3/15/2024
FDA Adcomm Backs Geron’s Anemia Drug for Blood Cancer
FDA Adcomm Backs Geron’s Anemia Drug for Blood Cancer 3/15/2024
FDA Approves Madrigal’s Rezdiffra as First MASH Therapy
FDA Approves Madrigal’s Rezdiffra as First MASH Therapy 3/15/2024
AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline
AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases.
The proposed acquisition will bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline and expand on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism.
AstraZeneca Boosts Rare Disease Portfolio with $1.05B Amolyt Acquisition
AstraZeneca Boosts Rare Disease Portfolio with $1.05B Amolyt Acquisition 3/14/2024
BIO Boots WuXi AppTec from Trade Group Amid US National Security Concerns
BIO Boots WuXi AppTec from Trade Group Amid US National Security Concerns 3/14/2024
ADC Biotech Tubulis Closes Upsized $138M Financing Round
ADC Biotech Tubulis Closes Upsized $138M Financing Round 3/14/2024
Recently Laid Off? Contract Work Could Be an Attractive Option
Recently Laid Off? Contract Work Could Be an Attractive Option 3/14/2024
Vertex Fails to Convince UK Watchdog of CRISPR Therapy Casgevy’s Value
Vertex Fails to Convince UK Watchdog of CRISPR Therapy Casgevy’s Value 3/14/2024
Mirum Secures Livmarli’s Expansion into Familial Intrahepatic Cholestasis
Mirum Secures Livmarli’s Expansion into Familial Intrahepatic Cholestasis 3/14/2024
Merck to Start Trials of New HPV Vaccine and Single-Dose Gardasil Shot
Merck to Start Trials of New HPV Vaccine and Single-Dose Gardasil Shot 3/14/2024
Career Coach: How to Truly Tailor a Resume
Career Coach: How to Truly Tailor a Resume 3/14/2024
PhRMA Loses Another Legal Battle as Court Sides with Arkansas Over Drug Discount Program
PhRMA Loses Another Legal Battle as Court Sides with Arkansas Over Drug Discount Program 3/14/2024
World Pharma News
- U.S. FDA approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy for adults with Hemophilia B
- AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
- Researchers publish final results of key clinical trial for gene therapy for sickle cell disease
- Optimal timing maximises Paxlovid benefits for treating COVID-19
- European Commission approves Pfizer's EMBLAVEO® for patients with multidrug-resistant infections and limited treatment options